On April 11, 2023 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported that it will present data from 14 studies highlighting advances in precision oncology and cancer screening at the 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, April 14-19 in Orlando, Florida (Press release, Guardant Health, APR 11, 2023, View Source [SID1234629941]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We look forward to sharing new data at AACR (Free AACR Whitepaper), in particular research demonstrating the tremendous possibilities of epigenomic analysis in biomarker discovery and cancer care," said Helmy Eltoukhy, Guardant Health chairman and co-CEO. "These presentations show how gaining deeper insights into the tumor microenvironment can help us identify new potential biomarker targets for therapy and predictive markers for treatment resistance, quantify circulating tumor DNA, and contribute to better-informed patient care."
Multiple studies to be presented at the meeting highlight the new GuardantINFINITY sequencing platform and demonstrate the utility of its methylation sequencing and epigenomic analysis capabilities in biomarker discovery, therapy selection and response monitoring. In particular, studies show that:
Methylome sequencing with a liquid-only approach using the GuardantINFINITY platform can quantify circulating tumor DNA level and change with greater sensitivity and precision than genomic sequencing, making longitudinal ctDNA monitoring accessible to a broader range of patients. (Abstract 3123)
Cancer genomics alone provides little information on tumor phenotype or functional state, which are governed by epigenetic mechanisms, notably methylation of regulatory regions. The analytical validation of the GuardantINFINITY genomic and epigenomic liquid biopsy platform showed its potential for ultra-sensitive ctDNA detection for minimal residual disease and recurrence surveillance, tumor fraction quantitation for therapy monitoring, oncogenic virus detection, immunogenotyping, epigenotyping, and tumor phenotype characterization, representing a new standard in biomarker discovery. (Abstract 6601)
Full List of Guardant Health Presentations
Abstract
Poster
Title
Product
Sunday, April 16 | 1:30 – 5:00 pm
1052
29
Background variability in plasma ctDNA levels in patients with advanced lung cancer in the absence of treatment
Guardant360
Monday, April 17 | 9:00 am – 12:30 pm
LB123
6
Poorer outcomes in EGFR L858R-driven NSCLC treated with osimertinib may be addressed with novel combination of BLU-945 and osimertinib
GuardantINFORM
Monday, April 17 | 1:30 – 5:00 pm
3331
6
Highly sensitive blood-based multi-cancer screening device with tiered specificity based on diagnostic workflow
Shield
3123
9
A method for quantifying circulating tumor DNA level and molecular response using methylome sequencing
GuardantINFINITY
3128
14
Using Kmerizer, a germline and somatic genotyper for immune associated complex alleles in GuardantINFINITY, for immunotherapy response prediction using cfDNA
GuardantINFINITY
3125
21
Validation of a bioinformatic model for classifying non-tumor variants in a cell-free DNA liquid biopsy assay
GuardantINFINITY
Tuesday, April 18 | 1:30 – 5:00 pm
5573
30
Use of circulating tumor DNA (ctDNA) for early assessment of treatment response in patients with non-small cell lung cancer (NSCLC): A real-world (RW) analysis incorporating baseline ctDNA level and molecular response
GuardantINFORM
4264
13
The genomic landscape of RET fusions in non-small cell lung cancer and the impact of co-occurring genomic alterations on the efficacy of selective RET inhibitors
Guardant360
CT278
18
ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in a phase 1 study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers
Guardant360
Wednesday, April 19 | 9:00 am – 12:30 pm
6087
27
Mutation and co-mutation landscape of ERBB2 alterations in advanced NSCLC
Guardant360
6744
4
Cell-free DNA detection of alterations in the MAPK pathway in metastatic hormone receptor positive breast cancer: a multi-institutional analysis of incidence and clinical outcomes
Guardant360
6094
2
Longitudinal analysis of PARP inhibitor and platinum resistance in BRCA1/2m breast cancer using liquid biopsy
GuardantINFINITY
6601
6
Analytical validation of a robust integrated genomic and epigenomic liquid biopsy for biomarker discovery, therapy selection, and response monitoring
GuardantINFINITY
6603
8
BRCA1 promoter methylation in sporadic breast cancer patients detected by liquid biopsy
GuardantINFINITY
The full abstracts for Guardant Health and a list of all abstracts being presented at the meeting can be found at the AACR (Free AACR Whitepaper) website here.
For more information and updates from the meeting, follow Guardant Health on LinkedIn and Twitter or visit AACR (Free AACR Whitepaper) booth #2465.